Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Public ClinicalTrials.gov record NCT01750281. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)
Study identification
- NCT ID
- NCT01750281
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 212 participants
Conditions and interventions
Interventions
- Docetaxel 60 mg/m2 Drug
- Docetaxel 75 mg/m2 Drug
- Placebo Drug
- Selumetinib 75 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2012
- Primary completion
- Jan 26, 2016
- Completion
- Oct 30, 2022
- Last update posted
- Oct 23, 2023
2012 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Hollywood | Florida | 33028 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Marrero | Louisiana | 70072 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | New York | New York | 10011 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Hershey | Pennsylvania | 17033-0850 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01750281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2023 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01750281 live on ClinicalTrials.gov.